Clinical observation of 125I-labeled anti-alpha fetoprotein antibody radioimmunotherapy in hepatocellular carcinoma

Table 1 Pretreatment clinical characteristics of the treatment and control (A, B, C) groups

Characteristics	Treatment group	Control groups
		A	B	C
Cases	22	25	21	25
Sex (male/female)	20/2	25/0	20/1	24/1
Average age (yr)	46.4	42.6	43.7	45.3
Age range	27.65	28.71	30.6	31.64
Type, stage (II/III)
Simple type (case)	14/1	15/1	15/1	17/1
Cirrhotic type (case)	7/0	8/1	5/0	6/1
Tumor mass ≤ 7	2	7	6	8
Size (cm) 7.1 - 10	10	13	8	13
> 10	10	5	7	4
Node single	9	12	6	16
multiple	13	13	15	9
Portal vein tumor thrombus	9	11	6	9
AFP > 400 (μg/L)	20	25	21	18
< 25	2	0	0	7
HBsAg (+)	19	21	18	22

Table 2 Dose, cycle (times) number of 125I group and control (A, B, C) groups

Treatment program	125I		A		B	C
	I	≥ II	I	≥ II		I	≥ II
Targeted times, treatment (case)	6	16	8	17
Average/case (MBq)	163.5	382	388.5	984.9	treatment for 20-50 d
Median/case (MBq)	207.2p	340.4	392.2	936.1
Chemotherapy (case)	7	5	11	6	2	0	251
Including TAI, E (case)	7	3	4	1	2	13	3

¹25 cases treated by 2 cycles, among them 13 cases had once of TAI.

Table 3 Short term therapeutic effects, post treatment survival rate of the treatment group and control (A, B, C) groups

Therapeutic effect	Treatment group1		Control groups
			A		B	C
	22	162	25	172	21	25
CR + PR	31.6 (6/19)	37.5 (6/16)	4.0 (1/25)	5.9 (1/17)	4.8 (1/21)	8.0 (2/25)
CR + PR + MR	42.1 (8/19)	43.8 (7/16)	16.0 (4/25)	23.5 (4/17)	28.6 (6/21)	20.0 (5/25)
Survival ≥ 6 mon	68.4 (13/19)	75.0 (12/16)	28.0 (7/25)	41.2 (7/17)	42.9 (9/21)	52.0 (13/25)
Survival ≥ 12 mon	47.1 (8/17)	57.1 (8/14)	16.0 (4/25)	23.5 (4/17)	9.5 (2/21)	8.0 (2/25)
Still alive	7	7	1	1	0	0

¹Only in ¹²⁵I group 1 case reached CR;

²by 2 or more than 2 times of treatment.